| Followers | 236 |
| Posts | 10817 |
| Boards Moderated | 0 |
| Alias Born | 07/17/2006 |
Wednesday, October 23, 2013 9:24:22 AM
Thank you zum
I feel as if I have been a small voice crying in the wilderness..
Everybody looks at this and says oh it's OK, or its the company's fault, or the company's fault for going it alone..I say no, the company has done nothing wrong here.
The FDA has an agenda here, and somebody, or some company is behind this. So far all we have is a successful stock manipulation, and we know from the options actions that somebody had access to confidential FDA information. Nobody puts up that kind of money on Zombie options without insider information.
Follow the money and you will find the culprits..The company's lawyers should be asking for a full investigation by the SEC.
I doubt the principals inside the FDA have the balls to follow through and kill the SPA agreement. That's going to mean federal court and they are not going to be able to pull off the shit they did in their own Kangaroo court. Best guess they put some face saving measure a minor amendment to the sNDA and its back to business as usual. You see when you throw the stock market action in with this you bring criminal into play..and these bureaucrats don't want to end up in jail.
A federal trial involving stock market manipulation, and FDA subversion is going to make headlines for AMRN and it is going to give Vascepa the kind of publicity that money can not buy..
Also it only takes one congressman to pull the trigger and start a congressional investigation of the whole matter..Would a congressman be interested in doing this..Well you have to ask yourself one question, "Do congressman like publicity?"...Well do they..
":>) JL
I feel as if I have been a small voice crying in the wilderness..
Everybody looks at this and says oh it's OK, or its the company's fault, or the company's fault for going it alone..I say no, the company has done nothing wrong here.
The FDA has an agenda here, and somebody, or some company is behind this. So far all we have is a successful stock manipulation, and we know from the options actions that somebody had access to confidential FDA information. Nobody puts up that kind of money on Zombie options without insider information.
Follow the money and you will find the culprits..The company's lawyers should be asking for a full investigation by the SEC.
I doubt the principals inside the FDA have the balls to follow through and kill the SPA agreement. That's going to mean federal court and they are not going to be able to pull off the shit they did in their own Kangaroo court. Best guess they put some face saving measure a minor amendment to the sNDA and its back to business as usual. You see when you throw the stock market action in with this you bring criminal into play..and these bureaucrats don't want to end up in jail.
A federal trial involving stock market manipulation, and FDA subversion is going to make headlines for AMRN and it is going to give Vascepa the kind of publicity that money can not buy..
Also it only takes one congressman to pull the trigger and start a congressional investigation of the whole matter..Would a congressman be interested in doing this..Well you have to ask yourself one question, "Do congressman like publicity?"...Well do they..
":>) JL
Recent AMRN News
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
- New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients • GlobeNewswire Inc. • 11/09/2025 09:15:00 PM
- Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 • GlobeNewswire Inc. • 11/03/2025 01:30:00 PM
